Neumora Other Liab from 2010 to 2024
| NMRA Stock | 10.52 0.13 1.25% |
Other Liabilities | First Reported 2010-12-31 | Previous Quarter 722.2 K | Current Value 557.7 K | Quarterly Volatility 108.1 K |
Check Neumora Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neumora Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 634.6 K, Selling General Administrative of 30.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.06. Neumora financial statements analysis is a perfect complement when working with Neumora Therapeutics, Valuation or Volatility modules.
Neumora | Other Liab |
Latest Neumora Therapeutics,'s Other Liab Growth Pattern
Below is the plot of the Other Liab of Neumora Therapeutics, Common over the last few years. It is Neumora Therapeutics,'s Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neumora Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Other Liab | 10 Years Trend |
|
Other Liab |
| Timeline |
Neumora Other Liab Regression Statistics
| Arithmetic Mean | 435,993 | |
| Geometric Mean | 426,060 | |
| Coefficient Of Variation | 24.79 | |
| Mean Deviation | 79,989 | |
| Median | 386,000 | |
| Standard Deviation | 108,096 | |
| Sample Variance | 11.7B | |
| Range | 336.2K | |
| R-Value | 0.65 | |
| Mean Square Error | 7.2B | |
| R-Squared | 0.43 | |
| Significance | 0.01 | |
| Slope | 15,818 | |
| Total Sum of Squares | 163.6B |
Neumora Other Liab History
About Neumora Therapeutics, Financial Statements
Neumora Therapeutics, stakeholders use historical fundamental indicators, such as Neumora Therapeutics,'s Other Liab, to determine how well the company is positioned to perform in the future. Although Neumora Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neumora Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Neumora Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neumora Therapeutics, Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Liabilities | 722.2 K | 557.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Common Stock:Check out the analysis of Neumora Therapeutics, Correlation against competitors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Return On Assets (0.38) | Return On Equity (0.77) |
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.